This proposal requests five years of continued support for the Mayo General Clinical Research Center, now in its eighteenth year of operation. The last five years have been productive as evidenced by the increase in publications related to work performed at the GCRC. During this period there has been a significant increase in outpatient studies and visits. This will continue during the next 5 years and we project more than 6000 outpatient visits in the twenty-first year of the grant. With increased outpatient activity; there was initially a concomitant fall in inpatient activity; however, over the last two years, there has been a gradual increase in inpatient studies. We project more than 2000 inpatient bed-days in the twenty-first year of the grant. Other changes that have occurred during the last grant period include an increase in short labor-intensive studies, an increase in studies with more acutely ill patients and an increase in usage of the unit by new disciplines and investigations. These trends will continue during the next five years with the development of major programs in hypertension, ophthalmology, and oncology. During this last grant period, there was a dramatic expansion in the use of computers in clinical research at the GCRC resulting in the growth of the MAYO supported Research Computer Facility. In the next 5 years, we are planning for major changes and continued expansion in our computer resources with implementation of improved hardware (e.g., Unix workstations) and software (e.g., PROPHET and INGRES). The migration from the present system to this new environment will require significant program support. Recently, the CRC advisory committee has expanded its role of reviewing protocols, setting priorities, and establishing policies while working very closely with the program director to assure that studies done at the GCRC are of the highest quality. This expanded role of the Advisory Committee will continue during the next 5 years. The established protocol review process ensures appropriate and expert scientific and statistical review early during protocol development. The major on-going programs now using the resources of the MAYO GCRC include: diabetes mellitus, metabolic bone disease, calcium metabolism, lipolysis, surgical and medical gastroenterology, and cardiovascular disease. New growing programs that will be important components of the MAYO GCRC during the next 5 years include: studies of ciliary body function and aqueous humor formation by the Department of Ophthalmology; phase I, phase II, and pharmacology studies of anticancer agents by the Department of Oncology, and studies of hypertension. This core of major users is predominately extramurally funded, with a spectrum of investigators from new, young individuals to more experienced principle investigators.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000585-27
Application #
2546547
Study Section
General Clinical Research Centers Committee (CLR)
Project Start
1976-12-01
Project End
1999-11-30
Budget Start
1997-12-01
Budget End
1998-11-30
Support Year
27
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Dad, Taimur; Abebe, Kaleab Z; Bae, K Ty et al. (2018) Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep 3:619-624
Yu, Alan S L; Shen, Chengli; Landsittel, Douglas P et al. (2018) Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int 93:691-699
Kamimura, Daisuke; Suzuki, Takeki; Wang, Wanmei et al. (2018) Higher plasma leptin levels are associated with reduced left ventricular mass and left ventricular diastolic stiffness in black women: insights from the Genetic Epidemiology Network of Arteriopathy (GENOA) study. Hypertens Res 41:629-638
Nowak, Kristen L; You, Zhiying; Gitomer, Berenice et al. (2018) Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 29:571-578
Tirumanisetty, P; Prichard, D; Fletcher, J G et al. (2018) Normal values for assessment of anal sphincter morphology, anorectal motion, and pelvic organ prolapse with MRI in healthy women. Neurogastroenterol Motil 30:e13314
McKenzie, Katelyn A; El Ters, Mirelle; Torres, Vicente E et al. (2018) Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort. BMC Nephrol 19:378
Brosnahan, Godela M; Abebe, Kaleab Z; Rahbari-Oskoui, Frederic F et al. (2017) Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials. Curr Hypertens Rev 13:109-120
Kamimura, Daisuke; Suzuki, Takeki; Furniss, Anna L et al. (2017) Elevated serum osteoprotegerin is associated with increased left ventricular mass index and myocardial stiffness. J Cardiovasc Med (Hagerstown) 18:954-961
Chung, Jin Ook; Koutsari, Christina; Blachnio-Zabielska, Agnieszka U et al. (2017) Intramyocellular Ceramides: Subcellular Concentrations and Fractional De Novo Synthesis in Postabsorptive Humans. Diabetes 66:2082-2091
West, Nancy A; Lirette, Seth T; Cannon, Victoria A et al. (2017) Adiposity, Change in Adiposity, and Cognitive Decline in Mid- and Late Life. J Am Geriatr Soc 65:1282-1288

Showing the most recent 10 out of 1267 publications